Denali Therapeutics (DNLI) Receivables: 2018-2025
Historic Receivables for Denali Therapeutics (DNLI) over the last 5 years, with Sep 2025 value amounting to $1.9 million.
- Denali Therapeutics' Receivables rose 35.71% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year decrease of 19.95%. This contributed to the annual value of $1.5 million for FY2024, which is 56.14% down from last year.
- Latest data reveals that Denali Therapeutics reported Receivables of $1.9 million as of Q3 2025, which was up 35.71% from $1.4 million recorded in Q2 2025.
- Over the past 5 years, Denali Therapeutics' Receivables peaked at $16.8 million during Q2 2021, and registered a low of $1.4 million during Q2 2024.
- In the last 3 years, Denali Therapeutics' Receivables had a median value of $1.9 million in 2025 and averaged $2.1 million.
- Its Receivables has fluctuated over the past 5 years, first skyrocketed by 5,495.00% in 2021, then slumped by 63.15% in 2023.
- Denali Therapeutics' Receivables (Quarterly) stood at $16.8 million in 2021, then reached $9.3 million in 2022, then slumped by 63.15% to $3.4 million in 2023, then crashed by 56.14% to $1.5 million in 2024, then skyrocketed by 35.71% to $1.9 million in 2025.
- Its last three reported values are $1.9 million in Q3 2025, $1.4 million for Q2 2025, and $1.7 million during Q1 2025.